Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential
Authors:
- Steffie K NaberSNSteffie K Naber
- Suman KunduSKSuman Kundu
- Karen M KuntzKKKaren M Kuntz
- W David DotsonWDW David Dotson
- Marc S WilliamsMWMarc S Williams
- Ann G ZauberAZAnn G Zauber
- Ned CalongeNCNed Calonge
- Doris T ZallenDZDoris T Zallen
- Theodore G GaniatsTGTheodore G Ganiats
- Elizabeth M WebberEWElizabeth M Webber
- Katrina A B GoddardKGKatrina A B Goddard
- Nora B HenriksonNHNora B Henrikson
Open Access
- 14 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 4 (1) , pkz086
Abstract
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.Keywords
Funding Information
- National Cancer Institute (U01CA152959)
- Cancer Intervention and Surveillance Modeling Network
- Evaluation of Genomic Applications in Practice and Prevention
This publication has 45 references indexed in Scilit:
- How can polygenic inheritance be used in population screening for common diseases?Genetics in Medicine, 2013
- Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer DeathsNew England Journal of Medicine, 2012
- Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial--SCOREJNCI: Journal of the National Cancer Institute, 2011
- Polygenic susceptibility to prostate and breast cancer: implications for personalised screeningBritish Journal of Cancer, 2011
- The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancerHuman Genetics, 2010
- Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trialThe Lancet, 2010
- Cost of Care for Elderly Cancer Patients in the United StatesJNCI: Journal of the National Cancer Institute, 2008
- Patient Time Costs Associated With Cancer CareJNCI: Journal of the National Cancer Institute, 2007
- Polyp Miss Rate Determined by Tandem Colonoscopy: A Systematic ReviewAmerican Journal of Gastroenterology, 2006
- Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family‐cancer databaseInternational Journal of Cancer, 2002